.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Michael Schaefer

Leipzig / DE

Vorsitz

14.03.2024
10:15 – 11:45
Symposien
Joint Symposium SFB TRR 152 | Molecular Pharmacology of Transient Receptor Potential
Butenandt HS

Weitere Beteiligungen

13.03.2024
Poster Self-Study
P126
TRPA1 engages a non-canonical chemotherapy defense program by phosphorylation independent activation of MARCKS
Ion channels and membrane transporters
13.03.2024
Poster Self-Study
P113
Pharmacological activation of TRPV2 triggers mast cell degranulation
Ion channels and membrane transporters
13.03.2024
Poster Self-Study
P122
Molecular basis for TRPM7 inhibition by intracellular magnesium
Ion channels and membrane transporters
13.03.2024
Poster Self-Study
P121
Selective pharmacological inhibition of TRPM6 and TRPM7
Ion channels and membrane transporters
14.03.2024
Poster Self-Study
P268
Insulin release from beta cells: triggered by or loosely coupled to Ca_V channel activity?
Signal transduction and second messengers
14.03.2024
Poster Self-Study
P201
Compound screening identifies Nitroxolin as a novel inhibitor of NLRP3-dependent pyroptosis
Immunopharmacology / inflammation / anti-infectives